The objectives of therapy for gastroesophageal reflux disease (GERD) are (1) to alleviate symptoms, (2) promote healing of esophagitis, (3) avoid disease progression, and (4) prevent recurrence.

How does robot-assisted Nissen fundoplication compare with standard surgical therapy? To answer this question, the study authors randomly assigned 50 patients to either standard or robot-assisted ...

Barrett's esophagus (BE) is a state in which the distal portion of esophageal mucosa becomes lined with cylindrical epithelium as a result of adaptive remodeling. It is widely accepted that the ...

Receding of the gastric contents to the oesophagus is called gastroesophageal reflux and can lead to inflammatory changes in the oesophagus and oesophageal mucosa damage. Frequent recurrences of the ...

Gastroesophageal reflux disease (GERD) is commonly treated using laparoscopic Nissen fundoplication (LNF), which results in dysphagia in approximately 5–10% of patients. Blom et al. hypothesized that ...

Laparoscopic antireflux surgery is the standard of care for patients with GERD; however, the long-term outcome of three antireflux procedures (Nissen, Thal, and Toupet) have not been adequately ...

In the past 2 decades, acid suppressive medications such as proton pump inhibitors have remained the first-line therapy for patients with GERD. According to experts interviewed by Healio ...

1. Which doctor performs Nissen fundoplication? Nissen fundoplication is carried out by a gastroenterology surgeon. 2. Can gastroesophageal reflux disease be cured? Patients who undergo ...

CHARLOTTE, N.C. — Among patients who underwent lung transplantation, laparoscopic Toupet fundoplication provided objective acid reflux control and preserved lung function and foregut motility, ...

A laparoscopic Heller myotomy is a surgical procedure used to treat achalasia, a condition in which the esophagus doesn't push food and liquid into the stomach effectively and the lower esophageal ...

Phase 2 study of cabozantinib (cabo) and pembrolizumab (pembro) in metastatic gastric/gastroesophageal adenocarcinoma (mGEA) refractory to immune checkpoint inhibitors (ICIs).